Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

被引：0
|
作者：
J Cummings
M Zweifel
N Smith
P Ross
J Peters
G Rustin
P Price
M R Middleton
T Ward
C Dive
机构：
[1] Clinical and Experimental Pharmacology Group,Department of Medical Oncology
[2] Manchester Cancer Research Centre,Academic Department of Radiation Oncology
[3] Paterson Institute for Cancer Research,University of Oxford Department of Medical Oncology
[4] University of Manchester,undefined
[5] Manchester,undefined
[6] Mount Vernon Cancer Centre,undefined
[7] Middlesex,undefined
[8] Northwood HA6 2RN,undefined
[9] UK,undefined
[10] Drug Development Office,undefined
[11] Cancer Research UK,undefined
[12] 61 Lincoln's Inn Fields,undefined
[13] London WC2A 3PX,undefined
[14] UK,undefined
[15] University of Manchester,undefined
[16] The Christie NHS Foundation Trust,undefined
[17] Oxford Biomedical Research Centre Cancer Theme,undefined
[18] Churchill Hospital,undefined
来源：
British Journal of Cancer | 2012年 / 106卷
关键词：
OXi4503; vascular disrupting agent; phase I trial; cell death mechanisms; M30 ELISA; M65 ELISA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1766 / 1771
页数：5
相关论文
共 50 条
  • [31] Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
    Zweifel, M.
    Patterson, D. M.
    Padhani, A. R.
    Middleton, M. R.
    Price, P.
    Stratford, M. R.
    Ross, P.
    Halford, S.
    Goldberg, Z.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
    Matthew Burge
    Alessandra B. Francesconi
    Dusan Kotasek
    Rosa Fida
    Gregg Smith
    Andrew Wilks
    Paul A. Vasey
    Jason D. Lickliter
    [J]. Investigational New Drugs, 2013, 31 : 126 - 135
  • [33] Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent
    Burge, Matthew
    Francesconi, Alessandra B.
    Kotasek, Dusan
    Fida, Rosa
    Smith, Gregg
    Wilks, Andrew
    Vasey, Paul A.
    Lickliter, Jason D.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 126 - 135
  • [34] Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design
    Wang, Tao
    Wu, Chengyong
    Wang, Chengdi
    Zhang, Guiping
    Arnst, Kinsie E.
    Yao, Yijun
    Zhang, Zhixiong
    Wang, Yuxi
    Pu, Dan
    Li, Weimin
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 525 (01) : 148 - 154
  • [35] Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors
    Sessa, Cristiana
    Lorusso, Patricia
    Tolcher, Anthony
    Farace, Francoise
    Lassau, Nathalie
    Delmonte, Angelo
    Braghetti, Antonio
    Bahleda, Rastislav
    Cohen, Patrick
    Hospitel, Marie
    Veyrat-Follet, Christine
    Soria, Jean-Charles
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (17) : 4832 - 4842
  • [36] A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
    Nowak, Anna K.
    Brown, Chris
    Millward, Michael J.
    Creaney, Jenette
    Byrne, Michael J.
    Hughes, Brett
    Kremmidiotis, Gabriel
    Bibby, David C.
    Leske, Annabell F.
    Mitchell, Paul L. R.
    Pavlakis, Nick
    Boyer, Michael
    Stockler, Martin R.
    [J]. LUNG CANCER, 2013, 81 (03) : 422 - 427
  • [37] Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer
    Francesconi, A.
    Kotasek, D.
    Burge, M.
    Smith, G.
    Lickliter, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.
    Ward, TH
    Danson, S
    Dawson, M
    McGrath, H
    Denneny, O
    Cummings, J
    Dive, C
    Ranson, M
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 : S60 - S60
  • [39] Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
    Yamanaka, R
    Homma, J
    Yajima, N
    Tsuchiya, N
    Sano, M
    Kobayashi, T
    Yoshida, S
    Abe, T
    Narita, M
    Takahashi, M
    Tanaka, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (11) : 4160 - 4167
  • [40] Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
    Yamanaka, Ryuya
    Homma, Junpei
    Yajima, Naoki
    Sano, Masakazu
    Takahashi, Masuhiro
    [J]. MOLECULAR THERAPY, 2006, 13 : S106 - S106
12345